Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9980, pp. 1843 - 1852
Summary Background The optimum duration of first-line treatment with chemotherapy in combination with bevacizumab in patients with metastatic colorectal cancer...
Internal Medicine | SURVIVAL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | CLINICAL-TRIALS | COMBINATION CHEMOTHERAPY | INTERMITTENT | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | HEPATIC RESECTION | III TRIAL | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Antibodies, Monoclonal, Humanized - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Antimitotic agents | Chemotherapy | Colorectal cancer | Product development | Metastasis | Antineoplastic agents | Cancer | Medical treatment | Medical prognosis | Clinical trials | Drug dosages | Cancer therapies | Quality of life
Internal Medicine | SURVIVAL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | CLINICAL-TRIALS | COMBINATION CHEMOTHERAPY | INTERMITTENT | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | HEPATIC RESECTION | III TRIAL | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Antibodies, Monoclonal, Humanized - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Antimitotic agents | Chemotherapy | Colorectal cancer | Product development | Metastasis | Antineoplastic agents | Cancer | Medical treatment | Medical prognosis | Clinical trials | Drug dosages | Cancer therapies | Quality of life
Journal Article
Nederlands tijdschrift voor geneeskunde, ISSN 0028-2162, 05/2019, Volume 163
Favourable course of cancer of unknown primary Background Most patients with cancer of unknown primary have a very poor prognosis. Case description A...
Journal Article
Lancet Oncology, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 943 - 953
Summary Background Treatment options for recurrent glioblastoma are scarce, with second-line chemotherapy showing only modest activity against the tumour....
Hematology, Oncology and Palliative Medicine | MALIGNANT GLIOMA | SURVIVAL | EFFICACY | NEWLY-DIAGNOSED GLIOBLASTOMA | RESPONSE ASSESSMENT | IRINOTECAN | PATTERNS | II TRIAL | RADIOTHERAPY | ADJUVANT TEMOZOLOMIDE | ONCOLOGY | Follow-Up Studies | Humans | Lomustine - adverse effects | Middle Aged | Brain Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Bevacizumab | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasm Invasiveness - pathology | Adult | Female | Brain Neoplasms - mortality | Drug Therapy, Combination | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Glioblastoma - therapy | Disease-Free Survival | Maximum Tolerated Dose | Glioblastoma - pathology | Adolescent | Brain Neoplasms - therapy | Survival Analysis | Infusions, Intravenous | Neoplasm Staging | Glioblastoma - mortality | Lomustine - administration & dosage | Drug Combinations | Antimitotic agents | Care and treatment | Relapse | Chemotherapy | Clinical trials | Lomustine | Product development | Antineoplastic agents | Glioblastoma multiforme | Diseases | Cancer | Index Medicus
Hematology, Oncology and Palliative Medicine | MALIGNANT GLIOMA | SURVIVAL | EFFICACY | NEWLY-DIAGNOSED GLIOBLASTOMA | RESPONSE ASSESSMENT | IRINOTECAN | PATTERNS | II TRIAL | RADIOTHERAPY | ADJUVANT TEMOZOLOMIDE | ONCOLOGY | Follow-Up Studies | Humans | Lomustine - adverse effects | Middle Aged | Brain Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Bevacizumab | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasm Invasiveness - pathology | Adult | Female | Brain Neoplasms - mortality | Drug Therapy, Combination | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Glioblastoma - therapy | Disease-Free Survival | Maximum Tolerated Dose | Glioblastoma - pathology | Adolescent | Brain Neoplasms - therapy | Survival Analysis | Infusions, Intravenous | Neoplasm Staging | Glioblastoma - mortality | Lomustine - administration & dosage | Drug Combinations | Antimitotic agents | Care and treatment | Relapse | Chemotherapy | Clinical trials | Lomustine | Product development | Antineoplastic agents | Glioblastoma multiforme | Diseases | Cancer | Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 05/2018, Volume 19, Issue 5, pp. 616 - 628
Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America....
CAPECITABINE | PERIOPERATIVE CHEMOTHERAPY | DOSE-ESCALATION | NODAL DISSECTION | CISPLATIN | ONCOLOGY | I-II | ADENOCARCINOMA | POSTOPERATIVE CHEMORADIOTHERAPY | FLUOROURACIL | III TRIAL | Neoadjuvant therapy | Chemotherapy | Stomach cancer | Analysis | Cancer
CAPECITABINE | PERIOPERATIVE CHEMOTHERAPY | DOSE-ESCALATION | NODAL DISSECTION | CISPLATIN | ONCOLOGY | I-II | ADENOCARCINOMA | POSTOPERATIVE CHEMORADIOTHERAPY | FLUOROURACIL | III TRIAL | Neoadjuvant therapy | Chemotherapy | Stomach cancer | Analysis | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2011, Volume 29, Issue 35, pp. 4633 - 4640
Purpose Neoadjuvant chemoradiotherapy for rectal cancer can result in complete disappearance of tumor and involved nodes. In patients without residual tumor on...
SURVIVAL | INTERVAL | SURGERY | RATES | TRANSANAL ENDOSCOPIC MICROSURGERY | LOCAL EXCISION | ONCOLOGY | CHEMORADIOTHERAPY | NONOPERATIVE TREATMENT | NEOADJUVANT RADIATION-THERAPY | PATHOLOGICAL COMPLETE RESPONSE | Fluorouracil - analogs & derivatives | Follow-Up Studies | Capecitabine | Deoxycytidine - administration & dosage | Humans | Middle Aged | Male | Treatment Outcome | Chemoradiotherapy | Rectal Neoplasms - radiotherapy | Disease-Free Survival | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Observation | Female | Neoadjuvant Therapy | Aged | Rectal Neoplasms - pathology | Rectal Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Cohort Studies
SURVIVAL | INTERVAL | SURGERY | RATES | TRANSANAL ENDOSCOPIC MICROSURGERY | LOCAL EXCISION | ONCOLOGY | CHEMORADIOTHERAPY | NONOPERATIVE TREATMENT | NEOADJUVANT RADIATION-THERAPY | PATHOLOGICAL COMPLETE RESPONSE | Fluorouracil - analogs & derivatives | Follow-Up Studies | Capecitabine | Deoxycytidine - administration & dosage | Humans | Middle Aged | Male | Treatment Outcome | Chemoradiotherapy | Rectal Neoplasms - radiotherapy | Disease-Free Survival | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Observation | Female | Neoadjuvant Therapy | Aged | Rectal Neoplasms - pathology | Rectal Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Cohort Studies
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1459 - 1467
Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients and is often the result of reduced activity of the key metabolic enzyme...
5-FLUOROURACIL SENSITIVITY | ORAL CAPECITABINE | VARIANTS | ONCOLOGY | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | FLUOROURACIL PLUS LEUCOVORIN | PHASE-III | RISK | SEVERE TOXICITY | PHARMACOGENETICS IMPLEMENTATION CONSORTIUM | METASTATIC COLORECTAL-CANCER | Cancer patients | Care and treatment | Safety and security measures | Health aspects | Analysis | Cancer
5-FLUOROURACIL SENSITIVITY | ORAL CAPECITABINE | VARIANTS | ONCOLOGY | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | FLUOROURACIL PLUS LEUCOVORIN | PHASE-III | RISK | SEVERE TOXICITY | PHARMACOGENETICS IMPLEMENTATION CONSORTIUM | METASTATIC COLORECTAL-CANCER | Cancer patients | Care and treatment | Safety and security measures | Health aspects | Analysis | Cancer
Journal Article
European Journal of Cancer, ISSN 0959-8049, 01/2019, Volume 107, pp. 60 - 67
Fluoropyrimidine therapy including capecitabine or 5-fluorouracil can result in severe treatment-related toxicity in up to 30% of patients. Toxicity is often...
Cost-analysis | Fluoropyrimidines | Pharmacogenetics | Genotyping | Toxicity | DPYD | Dihydropyrimidine dehydrogenase | PREDICTOR | FLUOROURACIL PLUS LEUCOVORIN | METASTATIC COLORECTAL-CANCER | DEFICIENCY | ORAL CAPECITABINE | 5-FLUOROURACIL | ONCOLOGY | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Cancer
Cost-analysis | Fluoropyrimidines | Pharmacogenetics | Genotyping | Toxicity | DPYD | Dihydropyrimidine dehydrogenase | PREDICTOR | FLUOROURACIL PLUS LEUCOVORIN | METASTATIC COLORECTAL-CANCER | DEFICIENCY | ORAL CAPECITABINE | 5-FLUOROURACIL | ONCOLOGY | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Cancer
Journal Article
Oncologist, ISSN 1083-7159, 02/2017, Volume 22, Issue 2, pp. 222 - 235
The incidence of brain metastases of solid tumors is increasing. Local treatment of brain metastases is generally straightforward: cranial radiotherapy (e.g.,...
Systemic therapy | Monoclonal antibodies | Brain metastases | Radiotherapy | Toxicity | Molecular targeted agents | CEREBROSPINAL-FLUID CONCENTRATIONS | WHOLE-BRAIN RADIOTHERAPY | RADIATION-THERAPY | P-GLYCOPROTEIN | CELL LUNG-CANCER | BREAST-CANCER | PHASE-II TRIAL | STEREOTACTIC RADIOSURGERY | ONCOLOGY | LEPTOMENINGEAL METASTASES | MULTIDRUG-RESISTANCE | Humans | Brain Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Cranial Irradiation - methods | Neoplasms - drug therapy | Brain Neoplasms - secondary | Neoplasm Metastasis | Female | Neoplasms - radiotherapy | Antineoplastic Agents - pharmacology | Brain Neoplasms - radiotherapy | Neoplasms - pathology | Neuro‐Oncology
Systemic therapy | Monoclonal antibodies | Brain metastases | Radiotherapy | Toxicity | Molecular targeted agents | CEREBROSPINAL-FLUID CONCENTRATIONS | WHOLE-BRAIN RADIOTHERAPY | RADIATION-THERAPY | P-GLYCOPROTEIN | CELL LUNG-CANCER | BREAST-CANCER | PHASE-II TRIAL | STEREOTACTIC RADIOSURGERY | ONCOLOGY | LEPTOMENINGEAL METASTASES | MULTIDRUG-RESISTANCE | Humans | Brain Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Cranial Irradiation - methods | Neoplasms - drug therapy | Brain Neoplasms - secondary | Neoplasm Metastasis | Female | Neoplasms - radiotherapy | Antineoplastic Agents - pharmacology | Brain Neoplasms - radiotherapy | Neoplasms - pathology | Neuro‐Oncology
Journal Article
BBA - Molecular Basis of Disease, ISSN 0925-4439, 03/2017, Volume 1863, Issue 3, pp. 721 - 730
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (5FU). Genetic variations in DPD have emerged...
Pharmacogenetics | Dihydropyrimidine dehydrogenase | 5-Fluorouracil | Capecitabine | Toxicity | DPYD | 5-FLUOROURACIL TOXICITY | III COLON-CANCER | ENZYME-ACTIVITY | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | ADJUVANT TREATMENT | CLINICAL-RELEVANCE | GENE | COLORECTAL-CANCER | INTRAGENIC REARRANGEMENTS | SINGLE NUCLEOTIDE POLYMORPHISMS | VARIANTS | DIHYDROPYRIMIDINE DEHYDROGENASE GENE | BIOCHEMISTRY & MOLECULAR BIOLOGY | FLUOROURACIL | DEFICIENCY | BIOPHYSICS | Genetic research | Genetic aspects | Messenger RNA | Analysis | Medical research | Enzymes | Medical colleges | Medical genetics | Medicine, Experimental | Index Medicus
Pharmacogenetics | Dihydropyrimidine dehydrogenase | 5-Fluorouracil | Capecitabine | Toxicity | DPYD | 5-FLUOROURACIL TOXICITY | III COLON-CANCER | ENZYME-ACTIVITY | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | ADJUVANT TREATMENT | CLINICAL-RELEVANCE | GENE | COLORECTAL-CANCER | INTRAGENIC REARRANGEMENTS | SINGLE NUCLEOTIDE POLYMORPHISMS | VARIANTS | DIHYDROPYRIMIDINE DEHYDROGENASE GENE | BIOCHEMISTRY & MOLECULAR BIOLOGY | FLUOROURACIL | DEFICIENCY | BIOPHYSICS | Genetic research | Genetic aspects | Messenger RNA | Analysis | Medical research | Enzymes | Medical colleges | Medical genetics | Medicine, Experimental | Index Medicus
Journal Article
Acta Oncologica, ISSN 0284-186X, 11/2013, Volume 52, Issue 8, pp. 1786 - 1788
ONCOLOGY | Prognosis | Follow-Up Studies | Humans | Ipilimumab | Antibodies, Monoclonal - therapeutic use | Survival Rate | Melanoma - secondary | Uveal Neoplasms - drug therapy | Uveal Neoplasms - secondary | Netherlands | Uveal Neoplasms - immunology | Melanoma - immunology | Immunotherapy | Melanoma - drug therapy | Adolescent | Retrospective Studies | Neoplasm Staging
Journal Article
Radiotherapy and Oncology, ISSN 0167-8140, 2013, Volume 107, Issue 2, pp. 184 - 188
Abstract Purpose To investigate the toxicity of nelfinavir, administered during preoperative chemoradiotherapy (CRT) in patients with locally advanced rectal...
Hematology, Oncology and Palliative Medicine | Phase I | Rectal cancer | Chemoradiation | Nelfinavir | INDINAVIR | CELLS | MANAGEMENT | VIVO | CHEMORADIOTHERAPY | PREOPERATIVE RADIATION | PATHWAY | COLORECTAL-CANCER | MUTATIONS | HIV PROTEASE INHIBITOR | ONCOLOGY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Nelfinavir - therapeutic use | Humans | Middle Aged | Male | Combined Modality Therapy | Rectal Neoplasms - therapy | Chemoradiotherapy | Nelfinavir - blood | Nelfinavir - adverse effects | Dose-Response Relationship, Drug | Female | Aged | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Clinical trials | Antiviral agents | Colorectal cancer
Hematology, Oncology and Palliative Medicine | Phase I | Rectal cancer | Chemoradiation | Nelfinavir | INDINAVIR | CELLS | MANAGEMENT | VIVO | CHEMORADIOTHERAPY | PREOPERATIVE RADIATION | PATHWAY | COLORECTAL-CANCER | MUTATIONS | HIV PROTEASE INHIBITOR | ONCOLOGY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Nelfinavir - therapeutic use | Humans | Middle Aged | Male | Combined Modality Therapy | Rectal Neoplasms - therapy | Chemoradiotherapy | Nelfinavir - blood | Nelfinavir - adverse effects | Dose-Response Relationship, Drug | Female | Aged | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Clinical trials | Antiviral agents | Colorectal cancer
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4774, 01/2013, Volume 10, Issue 1, pp. 12 - 13
Preoperative 5-fluorouracil-based chemoradiation with optimal surgery provides very effective local control in locally advanced rectal cancer. Does adding...
Radiation-Sensitizing Agents - therapeutic use | Radiotherapy Dosage | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Clinical Trials as Topic | Combined Modality Therapy | Rectal Neoplasms - therapy | Care and treatment | Colorectal cancer | Adjuvant treatment | Forecasts and trends | Radiotherapy | Methods | Cancer
Radiation-Sensitizing Agents - therapeutic use | Radiotherapy Dosage | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Clinical Trials as Topic | Combined Modality Therapy | Rectal Neoplasms - therapy | Care and treatment | Colorectal cancer | Adjuvant treatment | Forecasts and trends | Radiotherapy | Methods | Cancer
Journal Article